Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.49 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5467216 | 0.84 | L3MBTL1 (0.58) | OPRM1OPRL1OPRD1OPRK1SMN1; SMN2 | |
| SCHEMBL1945523 | 0.81 | OPRM1 (0.59) | OPRM1OPRL1OPRD1OPRK1SMN1; SMN2 | |
| SCHEMBL986690 | 0.78 | GPR119 (0.47) | OPRM1OPRL1OPRD1OPRK1GPR119 | |
| SCHEMBL1118397 | 0.77 | GPR119 (0.47) | OPRL1OPRD1OPRK1GPR119USP2 | |
| SCHEMBL3249913 | 0.76 | OPRD1 (0.49) | OPRM1OPRL1OPRD1OPRK1GPR119 | |
| SCHEMBL11956931 | 0.76 | GPR119 (0.53) | OPRM1OPRL1OPRD1OPRK1GPR119 | |
| SCHEMBL1807425 | 0.76 | OPRL1 (0.47) | OPRL1GPR119USP2SMN1; SMN2 | |
| SCHEMBL6594649 | 0.76 | DTYMK (0.43) | GPR119TSHRALOX15ATM | |
| SCHEMBL5759583 | 0.76 | CHRNA7 (0.38) | GPR119L3MBTL1TSHRALOX15ATM | |
| SCHEMBL6584117 | 0.75 | LMNA (0.46) | GPR119L3MBTL1TSHRALOX15ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8481524-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-09 | — | — | US | disclosed |
| US-8481524-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-09 | — | — | US | disclosed |
| US-20110136789-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-09 | — | — | US | disclosed |
| US-20110136789-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-09 | — | — | US | disclosed |
| EP-2205589-B1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMA (US) | 2011-03-23 | — | — | EP | disclosed |
| EP-2205589-B1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMA (US) | 2011-03-23 | — | — | EP | disclosed |
| EP-2205589-A2 | C-MET PROTEIN KINASE INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009045992-A2 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-04-09 | — | — | WO | disclosed |
| WO-2009045992-A2 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136789-A1 | C-MET PROTEIN KINASE INHIBITORS | MET, PRKCH, ABL1 | OPRM1 2565/4885OPRL1 3778/4885OPRD1 4004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.